KYORIN Pharmaceutical Co.,Ltd. (JP:4569) has released an update.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
KYORIN Pharmaceutical Co., Ltd. has signed a licensing agreement with Bayer AG to exclusively manufacture, develop, and commercialize a novel treatment for obstructive sleep apnea, BAY2925976. This strategic move aims to address the significant health risks associated with untreated OSA by expanding treatment options, potentially enhancing patient care and quality of life. The agreement includes an upfront payment of EUR 15 million to Bayer, with additional milestone and royalty payments based on future developments.
For further insights into JP:4569 stock, check out TipRanks’ Stock Analysis page.